NEW YORK, May 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Meta Expands AI Training With Employee Activity Tracking Tools
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 



